Cargando…
Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
BACKGROUND: Fibromyalgia (FM) is a chronic disorder characterized by widespread, persistent pain. Prospective and retrospective studies have demonstrated substantial health-care costs associated with FM in a number of countries. This study evaluated and compared health-resource use (HRU) and associa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637123/ https://www.ncbi.nlm.nih.gov/pubmed/23637545 http://dx.doi.org/10.2147/CEOR.S41111 |
_version_ | 1782267411928449024 |
---|---|
author | Knight, Tyler Schaefer, Caroline Chandran, Arthi Zlateva, Gergana Winkelmann, Andreas Perrot, Serge |
author_facet | Knight, Tyler Schaefer, Caroline Chandran, Arthi Zlateva, Gergana Winkelmann, Andreas Perrot, Serge |
author_sort | Knight, Tyler |
collection | PubMed |
description | BACKGROUND: Fibromyalgia (FM) is a chronic disorder characterized by widespread, persistent pain. Prospective and retrospective studies have demonstrated substantial health-care costs associated with FM in a number of countries. This study evaluated and compared health-resource use (HRU) and associated costs related to FM in routine clinical practice across the US, France, and Germany. METHODS: Two separate, cross-sectional, observational studies of subjects with FM were conducted: one in the US and one in France and Germany. HRU related to prescription medication, physician office visits, diagnostic tests, and hospitalizations was abstracted from chart review; patient out-of-pocket costs and lost productivity were collected via subject self-report. Costs were assigned to HRU based on standard algorithms. Direct and indirect costs were evaluated and compared by simple linear regression. RESULTS: A total of 442 subjects (203 US, 70 France, 169 Germany) with FM were analyzed. The mean (standard deviation) age in the US, France, and Germany was 47.9 (10.9), 51.2 (9.5), and 49.2 (9.8), respectively (P = 0.085). Most subjects were female (95% US, 83% France, 80% Germany) (P < 0.001). Adjusted annual direct costs per subject for FM were significantly higher in the US ($7087) than in France ($481, P < 0.001) or Germany ($2417, P < 0.001). Adjusted mean annual indirect costs per subject for FM were lower in the US ($6431) than in France ($8718) or Germany ($10,001), but represented a significant proportion of total costs in all countries. CONCLUSION: The significant HRU and costs associated with FM in the US, France, and Germany documented in this study highlight the substantial global economic burden of FM. Indirect costs represented a significant proportion of the total costs, particularly in Europe. Comparisons between the three countries show differences in HRU, with significantly higher direct costs in the US compared with France and Germany. |
format | Online Article Text |
id | pubmed-3637123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36371232013-05-01 Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States Knight, Tyler Schaefer, Caroline Chandran, Arthi Zlateva, Gergana Winkelmann, Andreas Perrot, Serge Clinicoecon Outcomes Res Original Research BACKGROUND: Fibromyalgia (FM) is a chronic disorder characterized by widespread, persistent pain. Prospective and retrospective studies have demonstrated substantial health-care costs associated with FM in a number of countries. This study evaluated and compared health-resource use (HRU) and associated costs related to FM in routine clinical practice across the US, France, and Germany. METHODS: Two separate, cross-sectional, observational studies of subjects with FM were conducted: one in the US and one in France and Germany. HRU related to prescription medication, physician office visits, diagnostic tests, and hospitalizations was abstracted from chart review; patient out-of-pocket costs and lost productivity were collected via subject self-report. Costs were assigned to HRU based on standard algorithms. Direct and indirect costs were evaluated and compared by simple linear regression. RESULTS: A total of 442 subjects (203 US, 70 France, 169 Germany) with FM were analyzed. The mean (standard deviation) age in the US, France, and Germany was 47.9 (10.9), 51.2 (9.5), and 49.2 (9.8), respectively (P = 0.085). Most subjects were female (95% US, 83% France, 80% Germany) (P < 0.001). Adjusted annual direct costs per subject for FM were significantly higher in the US ($7087) than in France ($481, P < 0.001) or Germany ($2417, P < 0.001). Adjusted mean annual indirect costs per subject for FM were lower in the US ($6431) than in France ($8718) or Germany ($10,001), but represented a significant proportion of total costs in all countries. CONCLUSION: The significant HRU and costs associated with FM in the US, France, and Germany documented in this study highlight the substantial global economic burden of FM. Indirect costs represented a significant proportion of the total costs, particularly in Europe. Comparisons between the three countries show differences in HRU, with significantly higher direct costs in the US compared with France and Germany. Dove Medical Press 2013-04-23 /pmc/articles/PMC3637123/ /pubmed/23637545 http://dx.doi.org/10.2147/CEOR.S41111 Text en © 2013 Knight et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Knight, Tyler Schaefer, Caroline Chandran, Arthi Zlateva, Gergana Winkelmann, Andreas Perrot, Serge Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States |
title | Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States |
title_full | Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States |
title_fullStr | Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States |
title_full_unstemmed | Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States |
title_short | Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States |
title_sort | health-resource use and costs associated with fibromyalgia in france, germany, and the united states |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637123/ https://www.ncbi.nlm.nih.gov/pubmed/23637545 http://dx.doi.org/10.2147/CEOR.S41111 |
work_keys_str_mv | AT knighttyler healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates AT schaefercaroline healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates AT chandranarthi healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates AT zlatevagergana healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates AT winkelmannandreas healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates AT perrotserge healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates |